Cargando…

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)

Detalles Bibliográficos
Autores principales:	Liu, Jin, Hu, Xiaoxia, Jia, Yanchun, Lu, Jin, Lee, Jae Hoon, Kim, Kihyun, Chen, Wenming, Liu, Aijun, Liu, Yang, Chen, Qi, Zhang, Chunyang, Suh, Cheolwon, Kim, Min Kyoung, Zhou, Fan, Chng, Wee Joo, Kumar, Shaji K., Durie, Brian, Hou, Jian, Fu, Weijun, Du, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179848/ https://www.ncbi.nlm.nih.gov/pubmed/33082513 http://dx.doi.org/10.1038/s41375-020-01060-w

Ejemplares similares

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Anaplastic morphology in IgD multiple myeloma
por: Roldán Galiacho, Verónica, et al.
Publicado: (2023)

AL Amyloidosis in a Patient with IgD Myeloma
por: Rafik, Hicham, et al.
Publicado: (2020)

IgD myeloma/immunoblastic lymphoma cells expressing cytokeratin.
por: Sewell, H. F., et al.
Publicado: (1986)

IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis
por: Colombo, I., et al.
Publicado: (2010)

Aggressive FLC Escape in a Patient with IgD Myeloma
por: Farges, Cédric, et al.
Publicado: (2015)

Clinical characteristics and survival of patients with IgD multiple myeloma
por: Li, Yi, et al.
Publicado: (2021)

Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience
por: Chong, Yong Pil, et al.
Publicado: (2008)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma
por: Chen, Jie, et al.
Publicado: (2017)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

IgD multiple myeloma with central nervous system involvement: A case report and literature review
por: Chen, Yi, et al.
Publicado: (2021)

More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis
por: Lu, Jin, et al.
Publicado: (2016)

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
por: Yan, Ge, et al.
Publicado: (2022)

Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma
por: Wang, Wei, et al.
Publicado: (2018)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion
por: Natori, Kazuhiko, et al.
Publicado: (2008)

Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma
por: Kishi, Seiji, et al.
Publicado: (2018)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report
por: De Santis, Elena, et al.
Publicado: (2016)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Retrospective analysis of 264 multiple myeloma patients
por: GENG, CHUANYING, et al.
Publicado: (2013)

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
por: Pisani, Francesco, et al.
Publicado: (2012)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
por: Husnain, Muhammad, et al.
Publicado: (2016)

Light chain deposition disease involving kidney and liver in a patient with IgD myeloma
por: Tsushima, Takafumi, et al.
Publicado: (2021)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review
por: Chen, Zhongchuan W., et al.
Publicado: (2013)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma
por: Chen, Wenming, et al.
Publicado: (2022)

SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma
por: Wu, Jian, et al.
Publicado: (2021)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d2o5c7ts25avftmamfoiojsead